Insilico Medicine has been nominated for the 2026 Prix Galien USA “Best Start-Up” Award in the Biotechnology category, marking the second consecutive year that the clinical-stage biotechnology company has received recognition from one of the life sciences industry’s most prominent innovation programs. The nomination comes as generative artificial intelligence moves from experimental research laboratories into the most demanding stages of pharmaceutical development, where candidate medicines must demonstrate safety, biological activity, manufacturing feasibility, and clinical benefit in carefully controlled trials. Insilico’s selection reflects the growing visibility of AI-native drug discovery companies and the increasing interest of pharmaceutical organizations in computational systems capable of influencing decisions across the entire research pipeline.
The Prix Galien was established in 1970 in honor of Galen, the ancient physician whose work helped shape the foundations of medical science and pharmacology. The international program now operates across more than 75 countries and recognizes advances that have the potential to transform human health. Unlike awards focused solely on a single scientific publication or laboratory discovery, the Prix Galien evaluates innovation in the broader context of medicine, including translational research, clinical development, technology, and patient impact. Insilico is nominated alongside companies such as Mammoth Biosciences, SandboxAQ, Iambic Therapeutics, Hemab Therapeutics, and Science Corporation, placing its AI-driven development model within a competitive field of emerging biotechnology ventures.
The nomination follows a year of major changes for Insilico. The company has advanced its lead internally discovered drug into Phase III clinical development, completed an initial public offering on the Main Board of the Hong Kong Stock Exchange under the ticker HKEX: 3696, and expanded the commercial use of its generative AI platform. Since its 2025 Prix Galien nomination, Insilico has also announced drug-discovery and out-licensing agreements with an aggregate potential value of approximately $10 billion. These agreements include a collaboration with Eli Lilly and Company valued at up to $2.75 billion, an agreement with SK Biopharmaceuticals valued at up to $2.5 billion, and a partnership with China Medical System Holdings Limited. The arrangements suggest that AI-based research platforms are increasingly being assessed not only as software products, but also as sources of commercially valuable therapeutic programs.
At the center of Insilico’s progress is rentosertib, also known as ISM001-055, a small-molecule inhibitor designed to block TNIK, or TRAF2- and NCK-interacting kinase. The compound is being developed for idiopathic pulmonary fibrosis, a progressive lung disease in which scar tissue accumulates in the pulmonary interstitium, gradually reducing the lungs’ ability to transfer oxygen. TNIK is involved in signaling pathways associated with fibrosis and cellular behavior, making it a potential therapeutic target for limiting disease progression. Rentosertib was created through Insilico’s Pharma.AI platform, which combines PandaOmics for target identification, Chemistry42 for generative molecular design, and InClinico for forecasting clinical development outcomes. Together, these systems are intended to connect biological data analysis, chemical synthesis planning, and clinical strategy in a single computational workflow.
In July 2026, Insilico initiated a prospective, randomized, 52-week global Phase III study of rentosertib in approximately 320 patients with idiopathic pulmonary fibrosis. The trial represents a decisive test of whether the compound’s effects observed in earlier development can translate into clinically meaningful outcomes in a larger and more diverse patient population. It also carries symbolic significance for the AI drug-discovery field: Insilico describes rentosertib as the first drug to reach pivotal-stage clinical development after both its novel biological target and molecular structure were identified using generative AI. The program received Breakthrough Therapy Designation from China’s Center for Drug Evaluation, a regulatory status intended to accelerate the development of medicines showing preliminary evidence of substantial improvement over available treatment options.
The Phase III program follows results from a Phase IIa clinical study published in Nature Medicine. In that trial, rentosertib produced dose-dependent changes in forced vital capacity, or FVC, a standard measure of how much air a person can forcibly exhale after taking a deep breath. After 12 weeks, patients receiving the highest tested dose experienced a mean FVC increase of 98.4 milliliters, while participants receiving placebo experienced a mean decline of 20.3 milliliters. Although short-term changes in FVC do not by themselves establish long-term efficacy or alter the standard of care, the difference provided a clinical signal supporting continued evaluation. In pulmonary fibrosis research, maintaining or improving lung function is particularly important because progressive loss of respiratory capacity is closely linked to worsening disability and mortality. The larger Phase III study will need to clarify the durability, statistical reliability, safety, and clinical significance of the observed effect.
Insilico’s broader approach was described in a separate study published in Nature Biotechnology, which detailed the path from target nomination to a preclinical candidate in less than 18 months. PandaOmics analyzes large biological datasets to prioritize disease-associated targets, potentially integrating information from genomic studies, scientific literature, and other molecular sources. Chemistry42 then generates and evaluates candidate structures according to properties such as target affinity, selectivity, physicochemical behavior, and synthetic accessibility. This is not simply a process of asking an algorithm to invent a molecule. Drug candidates must survive repeated cycles of computational prediction, medicinal chemistry, laboratory testing, pharmacology, toxicology, and formulation research. The value of generative AI lies in narrowing the search space and proposing chemically plausible options more rapidly than conventional approaches alone, while experimental science remains essential for determining whether those predictions hold true in living systems.
The company reports that its platform has supported more than 33 preclinical candidates across fibrosis, oncology, immunology, and other disease areas, with more than 13 programs receiving investigational new drug clearance. It also says that it works with 13 of the world’s 20 largest pharmaceutical companies, offering services and collaborations involving target discovery, generative chemistry, and clinical-development applications. Such numbers indicate that the commercial market for AI-enabled biotechnology is expanding, but they do not automatically prove that every computationally generated program will succeed. Drug development remains characterized by high attrition, and many compounds fail because of toxicity, inadequate exposure, insufficient efficacy, manufacturing challenges, or unexpected biological complexity. The ultimate test of Insilico’s model will therefore be the number of approved therapies and the benefits they deliver to patients, rather than the number of algorithms, partnerships, or preclinical candidates generated.
Alex Zhavoronkov, Insilico’s founder and chief executive, said the second consecutive nomination was meaningful because of the progress made by both the company and the field since its first recognition. He pointed to rentosertib’s transition into Phase III, the maturation of Insilico’s internal pipeline, and the company’s expanding pharmaceutical collaborations. The 2026 Prix Galien USA ceremony is scheduled for October 29 at the American Museum of Natural History in New York City. Whether Insilico ultimately receives the award, its nomination highlights a pivotal moment in biotechnology: generative AI is no longer being judged solely by the novelty of its predictions, but by its ability to produce drug candidates that withstand the increasingly rigorous sequence of biological experiments, human trials, regulatory review, and real-world medical use. For patients living with idiopathic pulmonary fibrosis, the most consequential outcome will be whether rentosertib can safely preserve lung function and slow disease progression where existing treatments remain limited.
Subject of Research: Generative artificial intelligence-driven drug discovery and the development of rentosertib (ISM001-055), a TNIK inhibitor for idiopathic pulmonary fibrosis.
Article Title: Insilico Medicine Nominated for 2026 Prix Galien USA Award as AI-Discovered Drug Enters Phase III
News Publication Date: August 18, 2026
Web References: https://www.insilico.com; https://mediasvc.eurekalert.org/Api/v1/Multimedia/82069734-aa61-4580-9b03-443164f9a57d/Rendition/low-res/Content/Public
References: Galien Foundation and Prix Galien USA; Nature Medicine study reporting Phase IIa rentosertib results; Nature Biotechnology study describing Insilico’s AI-enabled drug-discovery process.
Image Credits: Prix Galien, Insilico Medicine
Keywords: Insilico Medicine, generative AI, artificial intelligence, drug discovery, rentosertib, ISM001-055, TNIK inhibitor, idiopathic pulmonary fibrosis, Phase III clinical trial, biotechnology, Pharma.AI, PandaOmics, Chemistry42, InClinico, Prix Galien USA, pharmaceutical innovation
Tags: AI-driven drug discoveryAI’s role in pharmaceutical researchbiotech industry awardsbiotechnology startup recognitionclinical-stage biotechnology innovationscomputational systems in drug developmentgenerative artificial intelligence in pharmaimpact of AI on medicineInnovative healthcare technologiesInsilico Medicine achievementsPrix Galien award nominationstranslational research and clinical development
